Unlock stock picks and a broker-level newsfeed that powers Wall Street.

TSX Penny Stock Insights For May 2025

In This Article:

As the Canadian market navigates a complex landscape marked by trade developments and economic adjustments, the TSX has shown resilience, bolstered by strong performances in sectors like materials. In this context, investors might find value in exploring penny stocks—smaller or newer companies that can offer unique opportunities despite their somewhat outdated label. By focusing on those with robust financials and clear growth potential, these stocks may present compelling prospects for those willing to look beyond traditional investments.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

Westbridge Renewable Energy (TSXV:WEB)

CA$0.73

CA$73.84M

★★★★★★

NTG Clarity Networks (TSXV:NCI)

CA$1.73

CA$68.55M

★★★★★★

Thor Explorations (TSXV:THX)

CA$0.61

CA$419.14M

★★★★☆☆

Silvercorp Metals (TSX:SVM)

CA$4.90

CA$1.12B

★★★★★☆

Orezone Gold (TSX:ORE)

CA$1.08

CA$580.58M

★★★★★☆

Amerigo Resources (TSX:ARG)

CA$1.70

CA$283.88M

★★★★★☆

PetroTal (TSX:TAL)

CA$0.56

CA$539.85M

★★★★★☆

Pulse Seismic (TSX:PSD)

CA$2.62

CA$126.48M

★★★★★★

McCoy Global (TSX:MCB)

CA$3.35

CA$91.2M

★★★★★★

Findev (TSXV:FDI)

CA$0.49

CA$12.89M

★★★★★★

Click here to see the full list of 928 stocks from our TSX Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Haivision Systems

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Haivision Systems Inc. offers mission-critical, real-time video networking and visual collaboration solutions across Canada, the United States, and internationally with a market cap of CA$114.28 million.

Operations: The company generates CA$123.12 million in revenue from its Internet Telephone segment.

Market Cap: CA$114.28M

Haivision Systems Inc., with a market cap of CA$114.28 million, has demonstrated significant earnings growth over the past year at 63.5%, outpacing the Communications industry average. Despite this, recent earnings results for Q1 2025 showed a decline in sales to CA$28.16 million and a net loss of CA$1.08 million compared to last year's profit. The company's debt is well covered by operating cash flow, and its short-term assets exceed both short- and long-term liabilities, indicating solid financial management despite low return on equity at 2.4%. Haivision trades significantly below estimated fair value, suggesting potential undervaluation in the market.

TSX:HAI Financial Position Analysis as at May 2025
TSX:HAI Financial Position Analysis as at May 2025

NervGen Pharma

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: NervGen Pharma Corp. is a clinical-stage biotech company focused on developing pharmaceutical treatments for nervous system damage, with a market cap of CA$212.25 million.